Pancreatic cyst

ClearNote Health Joins the Pancreatic Cancer Early Detection (PRECEDE) Consortium in New Partnership to Reduce Cancer Mortality

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Health, Oncology, Other Health, Nucleic acid thermodynamics, Pancreatic cyst, Pancreas, Associate professor, Type 2 diabetes, McGill University, Disease, Risk, Cancer, Machine learning, Survival rate, Annual general meeting, Pancreatic cancer, Algorithm, Patient, DNA, Pharmaceutical industry, Medical imaging

ClearNote® Health, a cancer detection company focused on identifying cancer earlier in people at high risk for the deadliest cancers to enable longer lives, today announced it has signed an agreement to partner with the Pancreatic Cancer Early Detection (PRECEDE) Consortium .

Key Points: 
  • ClearNote® Health, a cancer detection company focused on identifying cancer earlier in people at high risk for the deadliest cancers to enable longer lives, today announced it has signed an agreement to partner with the Pancreatic Cancer Early Detection (PRECEDE) Consortium .
  • The PRECEDE Consortium is an international, multi-institutional collaborative group of experts working to improve early detection for those with a heritable risk for pancreatic cancer, or those with pancreatic cysts, through a novel model of collaboration and data sharing.
  • “ClearNote Health and PRECEDE share a common mission – to increase the survival rate for pancreatic cancer.
  • ClearNote Health will join and present at the PRECEDE Consortium’s Annual Meeting in New York City on December 6-7, 2023.

Biological Dynamics to Share Data at 2023 Early Detection of Cancer Conference in London, Highlighting Value of Exosome-based Liquid Biopsy Assay in Detecting Pancreatic Cysts

Retrieved on: 
Thursday, October 5, 2023
Oncology, Health, Health Technology, Other Health, General Health, Biotechnology, Pancreas, Biology, Physician, Exosome, Pancreatic cancer, Pancreatic cyst, Intraductal papillary mucinous neoplasm, Master of Science, Risk, IPMN, Survival, Cancer, Medical director, Patient, Q&A, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Conference, Expression, Pharmaceutical industry, MD

Biological Dynamics, Inc. , a leader in exosome enrichment technology for early disease detection, will present a “lightning talk” as part of the “Understanding Pre-cancers to Enable Early Detection” track at the Early Detection of Cancer Conference , Oct. 10-12, 2023, in London.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome enrichment technology for early disease detection, will present a “lightning talk” as part of the “Understanding Pre-cancers to Enable Early Detection” track at the Early Detection of Cancer Conference , Oct. 10-12, 2023, in London.
  • The ExoVita Pancreas assay leverages Biological Dynamics’ proprietary Verita™ technology, a novel platform that enriches exosomes and facilitates proteomic analysis.
  • This powerful method provides high-sensitivity detection of pancreatic cancer in its early stages, resulting in improved treatment options for this deadly disease.
  • Biological Dynamics is partnering with the PRECEDE consortium to validate the ExoVita Pancreas assay for both IPMNs and other patients at high risk for developing cancer.

NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs

Retrieved on: 
Wednesday, June 7, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Docetaxel, Ohio State University, Radiation, LSAM, Intraductal papillary mucinous neoplasm, Ohio State University Wexner Medical Center, Cyst, Clinical trial, Research, SOC, Doctor of Philosophy, ASCO, DDW, Patient, Risk, Ablation, Toxic epidermal necrolysis, Pancreatic cyst, Safety, Pharmaceutical industry, MD

NanOlogy LLC , a clinical-stage oncology company, announces a presentation of clinical research involving its large surface area microparticle (LSAM) investigational drugs at DDW 2023 in May and publication at ASCO Annual Meeting in June.

Key Points: 
  • NanOlogy LLC , a clinical-stage oncology company, announces a presentation of clinical research involving its large surface area microparticle (LSAM) investigational drugs at DDW 2023 in May and publication at ASCO Annual Meeting in June.
  • The DDW poster entitled “Intracystic Injection of Large Surface Area Microparticle Paclitaxel (LSAM-PTX) for Chemoablation of Intraductal Papillary Mucinous Neoplasms: Insights from an Expanded Access Protocol,” was presented by the research team of Somashekar Krishna, MD of The Ohio State University Wexner Medical Center.
  • The expanded access protocol prospectively evaluated safety and response of six subjects from the trial who received additional doses of LSAM-PTX.
  • “In this protocol, intracystic LSAM-PTX was safe and resulted in cyst volume and surface area reduction, morphological changes, and loss of pathogenic mutations,” said Dr. Krishna.

Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023

Retrieved on: 
Monday, June 5, 2023
Pancreatic cancer, Form 1095, CMS, Centers for Medicare & Medicaid Services, CEA, Glucose, Novita, Genetic testing, LCD, Medicare, MAC, Patient, Physician, Risk, Disease, Diagnosis, Mortality, Pancreatic cyst, Franciscan Ceramics, Pharmaceutical industry

The important information provided by PancraGEN helps support the differential diagnosis of pancreatic cancer by integrating the results of first-line tests and procedures with molecular test results.

Key Points: 
  • The important information provided by PancraGEN helps support the differential diagnosis of pancreatic cancer by integrating the results of first-line tests and procedures with molecular test results.
  • For the past decade, CMS has provided reimbursement for PancraGEN, and over that time nearly 70,000 patients have been tested on orders from physicians across the country.
  • We are extremely disappointed that CMS, through its Medicare Administrative Contractor (MAC), Novitas, is ending coverage for PancraGEN—an important and widely utilized test.
  • Yet, studies have shown that 60% to 80% of surgeries reveal indolent cysts that did not necessarily require surgery.

Amplified Sciences, Inc. revolutionizing early-detection diagnostics of pancreatic cancer and other diseases

Retrieved on: 
Tuesday, March 14, 2023
Cancer, Research, Pancreas, Purdue Research Park, Pancreatic cancer, Foundry, Prognosis, Gastroenterology, Cyst, Risk, Life, Biomarker, Davisson, Eli Lilly and Company, Pancreatic cyst, Death, Medicare, Chronic kidney disease, Student, Eli Lilly, Diagnosis, Malignancy, Gold, Progress, Doctor of Philosophy, Culture, Intellectual property, Pharmaceutical industry, Medical imaging, Cryptocurrency, Purdue University

“Earlier detection, followed by surgical removal, has a much better prognosis,” said Diana Caldwell, Amplified Sciences’ chief executive officer.

Key Points: 
  • “Earlier detection, followed by surgical removal, has a much better prognosis,” said Diana Caldwell, Amplified Sciences’ chief executive officer.
  • “We also hope that, with early detection, scientists can identify interventions that can impact early stage pancreatic cancer.
  • Then a “collusion of multiple things” turned his attention to pancreatic cancer diagnosis, including relevant professional connections and personal considerations: Six people in his life had died of pancreatic cancer.
  • “And the patient is waiting for us, all of us in the industry, to deliver these life-saving diagnostics to them.

Biological Dynamics and Oregon Health & Science University Collaborate on Early-Stage Pancreatic Cancer Detection Study

Retrieved on: 
Wednesday, March 1, 2023
Oncology, Health, Surgery, Clinical Trials, Research, Science, Biotechnology, Oregon Health and Science University Center for Women's Health, Oregon Health & Science University, Biological Dynamics of Forest Fragments Project, Doctor of Philosophy, Quality of life, MD, Survival, Diagnosis, PDAC, Sheppard, Pancreatic cancer, Disease, Partnership, Biomarker, Pancreas, Patient, DRS, Sears, Pancreatic cyst, Medical genetics, Neoadjuvant therapy, OHSU, Blood, Biology, FACS, Pharmaceutical industry

Biological Dynamics, Inc. , a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) to study its ExoVita™ Pancreas assay.

Key Points: 
  • Biological Dynamics, Inc. , a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) to study its ExoVita™ Pancreas assay.
  • The Brenden-Colson Center has a robust, integrated clinical-translational interface to drive innovative patient care and nourish scientific collaborations.
  • The ExoVita Pancreas assay significantly improves the care of patients at high risk for pancreatic cancer through earlier detection.
  • “We have a long-standing relationship with Oregon Health & Science University and look forward to collaborating to evaluate the clinical validity of our ExoVita Pancreas test,” said Paul Billings, MD, PhD, CEO of Biological Dynamics.

NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts

Retrieved on: 
Tuesday, December 20, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, Patient, Cyst, U.S. FDA, Neoplasm, Treatment, Paclitaxel, Patent, Pancreatic cancer, Toxic leukoencephalopathy, LSAM, FDA, Safety, Plasma, LAPC, Pancreas, Pancreatic cyst, Prostate, Lung, Research, Week, Medical imaging, Pharmaceutical industry

Certain mucinous pancreatic cysts are at high risk for progression to pancreatic cancer.

Key Points: 
  • Certain mucinous pancreatic cysts are at high risk for progression to pancreatic cancer.
  • Results from the trial are intended to support future research in this patient subset to evaluate whether intracystic LSAM-PTX can decrease the rate of progression.
  • The treatment is covered by a recently issued US patent ( 11,523,983 ) entitled Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles.
  • Enrollment is also complete (n=54) in a NanOlogy-sponsored clinical trial of intratumoral (IT) LSAM-PTX with systemic chemotherapy in locally advanced pancreatic cancer (LAPC).

Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern

Retrieved on: 
Monday, November 14, 2022
CMS, Diagnosis, Esophageal cancer, EBITDA, Comerica, COVID19, MicroRNA, Thyroid cancer, DSO, Risk, CEP, Pancreatic cancer, Safety, Pancreatic cyst, Physician, Sumathi Best Television Current Reporting Award, Nine Months, Security (finance), Lung cancer, Prognosis, Sale, Cancer, Franciscan Ceramics, Broad, Continuous operation, Borrowing base, Video game, Pharmaceutical industry, Iron ore, Pharma

Third quarter Net Revenue was $8.2 million, a 2% increase as compared to the same period of 2021.

Key Points: 
  • Third quarter Net Revenue was $8.2 million, a 2% increase as compared to the same period of 2021.
  • Our loss from continuing operations in the third quarter of 2022 was $1.3 million, slightly better than the prior year quarter.
  • We are very pleased with the improvement in liquidity resulting from the sale of the Pharma business in August, stated Tom Burnell, Ph.D., President and CEO of Interpace Biosciences.
  • However, the ThyGeNEXT pricing change impacted revenue and EBITDA by approximately $1.4 million for the third quarter of 2022, stated Mr. Burnell.

Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting

Retrieved on: 
Thursday, October 20, 2022
Physician, MicroRNA, U.S. Securities and Exchange Commission, Pancreatic cancer, Personal Data Privacy and Security Act of 2009, COVID19, Risk, BCR, Broad, Review, Natural borrowing limit, Diagnosis, Pancreatic cyst, LLC, Sumathi Best Television Current Reporting Award, Securities Exchange Act of 1934, Patient, Poster, CMS, Security (finance), Cancer, Esophageal cancer, Securities Act of 1933, American Thyroid Association, CEP, Technology, Private Securities Litigation Reform Act, ATA, Lung cancer, Mirna, Company, Doctor of Philosophy, Thyroid cancer, CEO, Safety, Prognosis, Franciscan Ceramics, GLOBE, EBITDA, Comerica, ITN, Terminology, Annual general meeting, Medical imaging, Pharmaceutical industry, Medical device

The findings are from an independent study and were shared today in a highlighted poster presentation during the American Thyroid Association (ATA) 2022 Annual Meeting (Poster #119).

Key Points: 
  • The findings are from an independent study and were shared today in a highlighted poster presentation during the American Thyroid Association (ATA) 2022 Annual Meeting (Poster #119).
  • A secondary, retrospective analysis was also performed with ThyraMIRv2, the Companys new miRNA pairwise expression profiler.
  • Additionally, a blinded analysis of pairwise miRNA expression profiling demonstrated improved accuracy from the original testing platform.
  • Because of these and other risks, uncertainties, and assumptions, undue reliance should not be placed on these forward-looking statements.

Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.

Retrieved on: 
Wednesday, August 31, 2022
Lung cancer, Franciscan Ceramics, COVID-19, Security (finance), CEO, Technology, Cancer, Securities Exchange Act of 1934, Safety, Securities Act of 1933, EBITDA, Pancreatic cancer, OTCQX, CMS, Sumathi Best Television Current Reporting Award, Physician, Diagnosis, Prognosis, CEP, Investment, U.S. Securities and Exchange Commission, Pancreatic cyst, GLOBE, Company, Comerica, Norwich Pharma Services, Risk, Borrowing base, Terminology, Broad, Thyroid cancer, Private Securities Litigation Reform Act, Acquisition, Growth, Review, Patient, Esophageal cancer, Pharmaceutical industry

PARSIPPANY, NJ, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (Interpace or the Company), a leader in enabling personalized medicine, has announced the closing of a definitive asset purchase agreement under which Flagship Biosciences, Inc. has acquired the Companys Pharma Services business (Interpace Pharma Solutions).

Key Points: 
  • PARSIPPANY, NJ, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (Interpace or the Company), a leader in enabling personalized medicine, has announced the closing of a definitive asset purchase agreement under which Flagship Biosciences, Inc. has acquired the Companys Pharma Services business (Interpace Pharma Solutions).
  • The Company will use the proceeds from the transaction for working capital requirements and investments to help drive the growth of its molecular diagnostics business.
  • "With the completion of the transaction, we expect the Companys operating cash flow to improve by nearly $5 million annually.
  • Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain including early diagnosis and prognostic planning.